Effects of the selective glucocorticoid receptor modulator compound a on bone metabolism and inflammation in male mice with collagen-induced arthritis

Endocrinology

Volumn 154, Issue 10, 2013, Pages 3719-3728

  Rauner, Martina ^a   Thiele, Sylvia ^a   Sinningen, Kathrin ^a   Winzer, Maria ^a   Salbach Hirsch, Juliane ^a   Gloe, Ina ^a   Peschke, Katrin ^a   Haegeman, Guy ^c   Tuckermann, Jan P ^d   Hofbauer, Lorenz C ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; COMPOUND A; DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTICULAR CARTILAGE; BONE DENSITY; BONE DESTRUCTION; BONE MASS; BONE METABOLISM; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG POTENCY; HISTOLOGY; INFLAMMATION; INFLAMMATORY CELL; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWELLING; T LYMPHOCYTE; TEMPERATURE;

ACETATES; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOSUPPRESSIVE AGENTS; JOINTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; OSTEOGENESIS; RANDOM ALLOCATION; RECEPTORS, GLUCOCORTICOID; T-LYMPHOCYTES; TYRAMINE;

EID: 84884695029     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2221     Document Type: Article

References (32)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219.
2. Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23:1525-1531.
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-1328. (Pubitemid 47389469)
4. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-1841. (Pubitemid 38402392)
5. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2011;11:517-531.
6. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;318:259-264. (Pubitemid 38526274)
7. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
8. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140:4382-4389. (Pubitemid 30666099)
9. Rauner M, Goettsch C, Stein N, et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology. 2011;152:103-112.
10. Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009;60:1427-1437.
11. Reichardt HM, Tuckermann JP, Göttlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20:7168-7173. (Pubitemid 34062308)
12. Baschant U, Frappart L, Rauchhaus U, et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci USA. 2011;108:19317-19322.
13. Schäcke H, Schottelius A, Do W, Strehlke P, Jaroch S, Schmees N. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 2004;101:227-232. (Pubitemid 38084232)
14. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem. 2010;120:96-104.
15. De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA. 2005;102:15827-15832. (Pubitemid 41552827)
16. Louw A, Swart P, DeKock SS, Van der Merwe KJ. Mechanism for the stabilization in vivo of the aziridine precursor 2-(4-acetoxyphe-nyl)-2-chloro- N-methyl-ethylammonium chloride by serum proteins. Biochem Pharmacol. 1997;53:189-197. (Pubitemid 27013474)
17. Louw A, Swart P. Salsola tuberculatiformis Botschantzev and an aziridine precursor analog mediate the in vivo increase in free corticosterone and decrease in corticosteroid-binding globulin in female Wistar rats. Endocrinology. 1999;140:2044-2053. (Pubitemid 30636441)
18. Dewint P, Gossye V, De Bosscher K, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol. 2008;180:2608-2615.
19. Wust S, Tischner D, John M, et al. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One. 2009;4:e8202.
20. Van Loo G, Sze M, Bougarne N, et al. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol. 2010;24:310-322.
21. Thiele S, Ziegler N, Tsourdi E, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res. 2012;27:2242-2250.
22. Inglis JJ, Criado G, Medghalchi M, et al. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther. 2007;9:R113.
23. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
24. Zhang Z, Zhang Z-Y, Schluesener HJ. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol. 2009;183:3081-3091.
25. Rauch A, Gossye V, Bracke D, et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 25:1323-1332.
26. Reuter KC, Grunwitz CR, Kaminski BM, Steinhilber D, Radeke HH, Stein J. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther. 2012;341:68-80.
27. Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V, et al. Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. PloS one. 2012;7:e35155.
28. Osman GE, Hannibal MC, Anderson JP, Lasky SR, Ladiges WC, Hood L. FVB/N [H2(q)] mouse is resistant to arthritis induction and exhibits a genomic deletion of T-cell receptor V β gene segments. Immunogenetics. 1999;49:851-859. (Pubitemid 29381446)
29. Louw A, Swart P, Allie F. Influence of an aziridine precursor on the in vitro binding parameters of rat and ovine corticosteroid-binding globulin (CBG). Biochem Pharmacol. 2000;59:167-175.
30. Cooper MS, Zhou H, Seibel MJ. Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets? J Bone Miner Res. 2012;27:2238-2241.
31. Sanchez BM, Lesch M, Brammer D, Bove SE, Thiel M, Kilgore KS. Use of a portable thermal imaging unit as a rapid, quantitative method of evaluating inflammation and experimental arthritis. J Pharmacol Toxicol Methods. 2008;57:169-175.
32. Brenner M, Braun C, Oster M, Gulko PS. Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity. Ann Rheum Dis. 2006;65:306-311. (Pubitemid 43268217)